Figure 5
From: An epigenetic vaccine model active in the prevention and treatment of melanoma
Prevention and treatment of melanoma by TSA-treated (irradiated) tumor cell vaccine. A) Vaccination with TSA-treated (500 nM for 48 h) and irradiated (2000 Gy) B16 cells prevents B16 tumor generation. Three weeks after s.c. inoculation of TSA-treated [TSA-radiation] or untreated [radiation] B16 (1 × 105) cells in B6 mice (16 in each group); all tumor-free mice were challenged s.c. with wild type B16 (1 × 105) cells and observed for 40 days. Percentage of tumor-free mice is presented in the Kaplan-Meier plot. B) Suppression of primary tumor growth by TSA-treated and irradiated melanoma vaccine. Groups of B6 mice bearing palpable B16 (5 days tumor growth) were treated s.c. with TSA-treated and irradiated B16 [TSA-radiation] or untreated irradiated B16 (1 × 105 cells) [radiation] in the opposite side of the trunk. A group of tumor-bearing mice did not receive any treatment [no treatment]. The number of tumor-free mice compared to total numbers used in each group is shown in parentheses at 42 days after treatment. C) Induction of long-term immunity in tumor-bearing mice treated with epigenetically altered melanoma vaccine. B16 tumor-bearing mice that became tumor-free following vaccine treatment were re-challenged s.c. with wild type B16 (1 × 105 cells). Kaplan-Meier plot shows tumor-free survival of mice in both TSA-radiation and radiation groups after re-challenge.